vs
Revvity（RVTY）与Unity Software Inc.（U）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是Unity Software Inc.的1.5倍（$772.1M vs $503.1M），Revvity净利率更高（12.7% vs -17.9%，领先30.6%），Unity Software Inc.同比增速更快（10.1% vs 5.9%），Revvity自由现金流更多（$161.8M vs $118.7M），过去两年Revvity的营收复合增速更高（9.0% vs 4.5%）
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
Unity Software Inc.是总部位于美国旧金山的游戏软件开发企业，2004年于丹麦成立时原名为Over the Edge Entertainment，2007年更为现名。公司核心产品Unity游戏引擎全球应用广泛，可用于开发各类电子游戏及其他互动应用，商业化授权服务覆盖全球客户。
RVTY vs U — 直观对比
营收规模更大
RVTY
是对方的1.5倍
$503.1M
营收增速更快
U
高出4.2%
5.9%
净利率更高
RVTY
高出30.6%
-17.9%
自由现金流更多
RVTY
多$43.1M
$118.7M
两年增速更快
RVTY
近两年复合增速
4.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $772.1M | $503.1M |
| 净利润 | $98.4M | $-90.0M |
| 毛利率 | — | 74.3% |
| 营业利润率 | 14.5% | -21.2% |
| 净利率 | 12.7% | -17.9% |
| 营收同比 | 5.9% | 10.1% |
| 净利润同比 | 3.9% | 26.7% |
| 每股收益（稀释后） | $0.86 | $-0.21 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收RVTYU
| Q4 25 | $772.1M | $503.1M | ||
| Q3 25 | $698.9M | $470.6M | ||
| Q2 25 | $720.3M | $440.9M | ||
| Q1 25 | $664.8M | $435.0M | ||
| Q4 24 | $729.4M | $457.1M | ||
| Q3 24 | $684.0M | $446.5M | ||
| Q2 24 | $691.7M | $449.3M | ||
| Q1 24 | $649.9M | $460.4M |
净利润RVTYU
| Q4 25 | $98.4M | $-90.0M | ||
| Q3 25 | $46.7M | $-126.4M | ||
| Q2 25 | $53.9M | $-108.8M | ||
| Q1 25 | $42.2M | $-77.6M | ||
| Q4 24 | $94.6M | $-122.7M | ||
| Q3 24 | $94.4M | $-124.7M | ||
| Q2 24 | $55.4M | $-125.6M | ||
| Q1 24 | $26.0M | $-291.1M |
毛利率RVTYU
| Q4 25 | — | 74.3% | ||
| Q3 25 | 53.6% | 74.4% | ||
| Q2 25 | 54.5% | 74.1% | ||
| Q1 25 | 56.5% | 73.8% | ||
| Q4 24 | — | 74.7% | ||
| Q3 24 | 56.3% | 74.9% | ||
| Q2 24 | 55.7% | 75.8% | ||
| Q1 24 | 54.6% | 68.6% |
营业利润率RVTYU
| Q4 25 | 14.5% | -21.2% | ||
| Q3 25 | 11.7% | -26.7% | ||
| Q2 25 | 12.6% | -26.9% | ||
| Q1 25 | 10.9% | -29.4% | ||
| Q4 24 | 16.3% | -27.1% | ||
| Q3 24 | 14.3% | -28.5% | ||
| Q2 24 | 12.4% | -28.8% | ||
| Q1 24 | 6.8% | -81.4% |
净利率RVTYU
| Q4 25 | 12.7% | -17.9% | ||
| Q3 25 | 6.7% | -26.9% | ||
| Q2 25 | 7.5% | -24.7% | ||
| Q1 25 | 6.4% | -17.8% | ||
| Q4 24 | 13.0% | -26.8% | ||
| Q3 24 | 13.8% | -27.9% | ||
| Q2 24 | 8.0% | -28.0% | ||
| Q1 24 | 4.0% | -63.2% |
每股收益（稀释后）RVTYU
| Q4 25 | $0.86 | $-0.21 | ||
| Q3 25 | $0.40 | $-0.30 | ||
| Q2 25 | $0.46 | $-0.26 | ||
| Q1 25 | $0.35 | $-0.19 | ||
| Q4 24 | $0.77 | $-0.30 | ||
| Q3 24 | $0.77 | $-0.31 | ||
| Q2 24 | $0.45 | $-0.32 | ||
| Q1 24 | $0.21 | $-0.75 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $919.9M | $2.1B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $7.3B | $3.2B |
| 总资产 | $12.2B | $6.8B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资RVTYU
| Q4 25 | $919.9M | $2.1B | ||
| Q3 25 | $931.4M | $1.9B | ||
| Q2 25 | $991.8M | $1.7B | ||
| Q1 25 | $1.1B | $1.5B | ||
| Q4 24 | $1.2B | $1.5B | ||
| Q3 24 | $1.2B | $1.4B | ||
| Q2 24 | $2.0B | $1.3B | ||
| Q1 24 | $1.7B | $1.2B |
股东权益RVTYU
| Q4 25 | $7.3B | $3.2B | ||
| Q3 25 | $7.4B | $3.2B | ||
| Q2 25 | $7.6B | $3.2B | ||
| Q1 25 | $7.6B | $3.2B | ||
| Q4 24 | $7.7B | $3.2B | ||
| Q3 24 | $7.9B | $3.2B | ||
| Q2 24 | $7.9B | $3.2B | ||
| Q1 24 | $7.8B | $3.2B |
总资产RVTYU
| Q4 25 | $12.2B | $6.8B | ||
| Q3 25 | $12.1B | $6.8B | ||
| Q2 25 | $12.4B | $6.7B | ||
| Q1 25 | $12.4B | $6.6B | ||
| Q4 24 | $12.4B | $6.7B | ||
| Q3 24 | $12.8B | $6.7B | ||
| Q2 24 | $13.4B | $6.7B | ||
| Q1 24 | $13.4B | $6.8B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $182.0M | $121.4M |
| 自由现金流经营现金流 - 资本支出 | $161.8M | $118.7M |
| 自由现金流率自由现金流/营收 | 21.0% | 23.6% |
| 资本支出强度资本支出/营收 | 2.6% | 0.5% |
| 现金转化率经营现金流/净利润 | 1.85× | — |
| 过去12个月自由现金流最近4个季度 | $509.4M | $403.9M |
8季度趋势，按日历期对齐
经营现金流RVTYU
| Q4 25 | $182.0M | $121.4M | ||
| Q3 25 | $138.5M | $155.4M | ||
| Q2 25 | $134.3M | $133.1M | ||
| Q1 25 | $128.2M | $13.0M | ||
| Q4 24 | $174.2M | $112.2M | ||
| Q3 24 | $147.9M | $122.4M | ||
| Q2 24 | $158.6M | $88.4M | ||
| Q1 24 | $147.6M | $-7.4M |
自由现金流RVTYU
| Q4 25 | $161.8M | $118.7M | ||
| Q3 25 | $120.0M | $151.3M | ||
| Q2 25 | $115.5M | $126.7M | ||
| Q1 25 | $112.2M | $7.3M | ||
| Q4 24 | $149.8M | $105.8M | ||
| Q3 24 | $125.6M | $115.2M | ||
| Q2 24 | $136.6M | $79.6M | ||
| Q1 24 | $129.7M | $-14.6M |
自由现金流率RVTYU
| Q4 25 | 21.0% | 23.6% | ||
| Q3 25 | 17.2% | 32.1% | ||
| Q2 25 | 16.0% | 28.7% | ||
| Q1 25 | 16.9% | 1.7% | ||
| Q4 24 | 20.5% | 23.1% | ||
| Q3 24 | 18.4% | 25.8% | ||
| Q2 24 | 19.7% | 17.7% | ||
| Q1 24 | 20.0% | -3.2% |
资本支出强度RVTYU
| Q4 25 | 2.6% | 0.5% | ||
| Q3 25 | 2.6% | 0.9% | ||
| Q2 25 | 2.6% | 1.5% | ||
| Q1 25 | 2.4% | 1.3% | ||
| Q4 24 | 3.4% | 1.4% | ||
| Q3 24 | 3.3% | 1.6% | ||
| Q2 24 | 3.2% | 2.0% | ||
| Q1 24 | 2.7% | 1.6% |
现金转化率RVTYU
| Q4 25 | 1.85× | — | ||
| Q3 25 | 2.97× | — | ||
| Q2 25 | 2.49× | — | ||
| Q1 25 | 3.03× | — | ||
| Q4 24 | 1.84× | — | ||
| Q3 24 | 1.57× | — | ||
| Q2 24 | 2.87× | — | ||
| Q1 24 | 5.67× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
U
| Grow Solutions | $338.2M | 67% |
| Create Solutions | $164.9M | 33% |
